1. Home
  2. MAS vs DVA Comparison

MAS vs DVA Comparison

Compare MAS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Masco Corporation

MAS

Masco Corporation

N/A

Current Price

$82.76

Market Cap

16.4B

Sector

Industrials

ML Signal

N/A

Logo DaVita Inc.

DVA

DaVita Inc.

N/A

Current Price

$161.80

Market Cap

14.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MAS
DVA
Founded
1929
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Misc Health and Biotechnology Services
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.4B
14.9B
IPO Year
1994
2003

Fundamental Metrics

Financial Performance
Metric
MAS
DVA
Price
$82.76
$161.80
Analyst Decision
Hold
Hold
Analyst Count
22
8
Target Price
$82.74
★ $222.29
AVG Volume (30 Days)
★ 2.1M
753.7K
Earning Date
10-28-2026
10-29-2026
Dividend Yield
★ 1.55%
N/A
EPS Growth
★ 2.66
N/A
EPS
3.81
★ 10.27
Revenue
$7,562,000,000.00
★ $13,643,069,000.00
Revenue This Year
$1.98
$4.38
Revenue Next Year
$2.08
$3.66
P/E Ratio
$21.72
★ $15.21
Revenue Growth
N/A
★ 6.46
52 Week Low
$58.16
$101.00
52 Week High
$87.86
$247.49

Technical Indicators

Market Signals
Indicator
MAS
DVA
Relative Strength Index (RSI) 55.77 35.65
Support Level $67.29 $145.58
Resistance Level $82.97 $194.64
Average True Range (ATR) 2.40 6.41
MACD -0.54 -3.03
Stochastic Oscillator 14.11 20.65

Price Performance

Historical Comparison
MAS
DVA

About MAS Masco Corporation

Masco is a global manufacturer of branded home improvement products, with a focus on plumbing fixtures (70% of revenue) and decorative architectural coatings (30% of revenue). The company primarily serves the repair and remodel market, with products such as faucets, showerheads, and paint sold through retail, wholesale, and e-commerce channels. Its portfolio includes well-known brands such as Delta, Hansgrohe, and Behr.

About DVA DaVita Inc.

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Share on Social Networks: